Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
Lexicon Pharmaceuticals executive Craig B. Granowitz, SVP and Chief Medical Officer, reported new equity awards. On February 12, 2026, he received 346,610 restricted stock units, each representing one share of common stock, and a stock option for 519,920 shares with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on continued service.
Lexicon Pharmaceuticals granted equity awards to senior vice president of discovery Suma Gopinathan. On February 12, 2026, she acquired 238,450 restricted stock units, each representing one share of common stock, and a stock option for 357,680 shares at an exercise price of $1.37 per share.
The RSUs vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, then 1/48th of the shares each month of continued service until fully vested by February 12, 2036.
Lexicon Pharmaceuticals, Inc. reported equity awards to senior vice president Lisa DeFrancesco. On February 12, 2026, she received 257,530 restricted stock units, each representing a right to one share of common stock, and 386,300 stock options with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock options vest 25% on the first anniversary of grant, with the remaining portion vesting monthly over the following three years, contingent on continued service.
Lexicon Pharmaceuticals executive Brian T. Crum, SVP, General Counsel and Secretary, reported equity awards on February 12, 2026. He was granted 299,710 restricted stock units, each representing the right to receive one share of common stock as they vest.
The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. Crum was also granted a stock option for 449,560 shares at an exercise price of $1.37 per share, vesting 25% after one year and the remainder in equal monthly installments over the next three years.
Lexicon Pharmaceuticals SVP and CFO Scott M. Coiante received new equity awards as part of his compensation. On February 12, 2026, he was granted 272,680 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in three equal installments on February 28 of each of the three years after the grant year.
On the same date, he also received 409,020 stock options with an exercise price of $1.37 per share, expiring on February 12, 2036. The option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, all held as direct ownership.
Lexicon Pharmaceuticals’ Chief Executive Officer and director Michael Exton reported equity awards dated February 12, 2026. He received 862,440 restricted stock units, each representing a right to one share of common stock. These restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year.
He was also granted a stock option for 1,293,670 shares of common stock at an exercise price of $1.37 per share. The option vests 25% on the first anniversary of the grant date and then 1/48th of the shares each month of continued service thereafter.
Avicenna Life Sci Master Fund LP and its general partner Avicenna Life Sci Master GP LLC reported their initial insider status in Lexicon Pharmaceuticals. As of February 2, 2026, the fund indirectly beneficially owned 1,538,462 shares of Lexicon common stock.
The filing identifies both Avicenna entities as a director and 10% owner group, with the common stock directly held by Avicenna Life Sci Master Fund LP. The reporting persons disclaim beneficial ownership of securities held by the other related reporting persons except to the extent of their pecuniary interest.
Lexicon Pharmaceuticals disclosed significant share purchases by investment entities tied to Invus and Artal as part of a financing that closed on February 2, 2026. Artal Participations S.a r.l. agreed to buy 22,400,000 common shares at $1.30 per share, assigning the right to purchase 3,846,154 of those shares to Invus Public Equities, L.P., which bought them directly from Lexicon at the same price. Avicenna Life Sci Master Fund LP purchased 1,538,462 common shares as part of an underwritten public offering.
Artal Participations S.a r.l. also agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock at $65.00 per share and obtained the right to buy up to an additional 94,854.88 preferred shares at the same price. Each preferred share will automatically convert into 50 common shares once shareholder approval is obtained and specified conditions are met; until then, the preferred shares are not convertible. The filing notes complex ownership chains among Artal, Invus and related entities, and each reporting person disclaims beneficial ownership of securities held by the others beyond its pecuniary interest.
Lexicon Pharmaceuticals’ major shareholders have updated their ownership and financing arrangements following a new capital raise. An investor group led by Artal and Invus now collectively reports beneficial ownership of 205,952,227 Lexicon common shares, representing approximately 48.2% of the 427,084,567 shares outstanding as of the recent financing.
Artal Participations agreed to buy 22,400,000 common shares for $29,120,000 and 367,145.12 shares of Series B convertible preferred stock for $23,864,432.80 in private placements. Invus Public Equities purchased 3,846,154 common shares for $5,000,000.20, and Avicenna Life Sci Master Fund bought 1,538,462 common shares for $2,000,000.60 as part of a 32,000,000‑share underwritten public offering with a 4,800,000‑share option. The new preferred stock will automatically convert into common shares at a 50‑to‑1 ratio once shareholders approve an increase in authorized common shares and related charter steps are completed, subject to antitrust clearance where applicable.
Lexicon Pharmaceuticals has arranged a large equity financing through a public stock sale and related private placements involving its longtime investor Invus. The company agreed to sell 32,000,000 common shares at $1.30 per share, with underwriters holding a 30‑day option for 4,800,000 additional shares, for expected gross proceeds of about $41.6 million (or $47.84 million if the option is fully exercised), before fees.
Concurrently, Invus affiliates are purchasing 22,400,000 common shares at the same price for a total of $29.12 million, and an Invus affiliate will buy multiple tranches of Series B convertible preferred stock at $65 per share for expected gross proceeds of about $23.86 million (or $30.03 million if an additional option is fully used). Each preferred share converts into 50 common shares once shareholders approve a new charter increasing authorized common stock, the board adopts and files that charter, and any required Hart‑Scott‑Rodino clearances are obtained. After the offerings and the preferred conversion, Invus and related entities are expected to hold about 51% of Lexicon’s outstanding common stock, giving them majority ownership.